Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Wen-Zhao Zhong, Qun Wang, Wei-Min Mao, Song-Tao Xu, Lin Wu, Yu-Cheng Wei, Yong-Yu Liu, Chun Chen, Ying Cheng, Rong Yin, Fan Yang, Sheng-Xiang Ren, Xiao-Fei Li, Jian Li, Cheng Huang, Zhi-Dong Liu, Shun Xu, Ke-Neng Chen, Shi-Dong Xu, Lun-Xu Liu, Ping Yu, Bu-Hai Wang, Hai-Tao Ma, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-Yang Liu, Qing Zhou, Yi-Long Wu, Wen-Zhao Zhong, Qun Wang, Wei-Min Mao, Song-Tao Xu, Lin Wu, Yu-Cheng Wei, Yong-Yu Liu, Chun Chen, Ying Cheng, Rong Yin, Fan Yang, Sheng-Xiang Ren, Xiao-Fei Li, Jian Li, Cheng Huang, Zhi-Dong Liu, Shun Xu, Ke-Neng Chen, Shi-Dong Xu, Lun-Xu Liu, Ping Yu, Bu-Hai Wang, Hai-Tao Ma, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-Yang Liu, Qing Zhou, Yi-Long Wu

Abstract

Purpose: ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079), a randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved disease-free survival (DFS) versus vinorelbine plus cisplatin (VP) in patients with epidermal growth factor receptor (EGFR) mutation-positive resected stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC). Here, we report the final overall survival (OS) results.

Methods: From September 2011 to April 2014, 222 patients from 27 sites were randomly assigned 1:1 to adjuvant gefitinib (n = 111) or VP (n = 111). Patients with resected stage II-IIIA (N1-N2) NSCLC and EGFR-activating mutation were enrolled, receiving gefitinib for 24 months or VP every 3 weeks for four cycles. The primary end point was DFS (intention-to-treat [ITT] population). Secondary end points included OS, 3-, 5-year (y) DFS rates, and 5-year OS rate. Post hoc analysis was conducted for subsequent therapy data.

Results: Median follow-up was 80.0 months. Median OS (ITT) was 75.5 and 62.8 months with gefitinib and VP, respectively (hazard ratio [HR], 0.92; 95% CI, 0.62 to 1.36; P = .674); respective 5-year OS rates were 53.2% and 51.2% (P = .784). Subsequent therapy was administered upon progression in 68.4% and 73.6% of patients receiving gefitinib and VP, respectively. Subsequent targeted therapy contributed most to OS (HR, 0.23; 95% CI, 0.14 to 0.38) compared with no subsequent therapy. Updated 3y DFS rates were 39.6% and 32. 5% with gefitinib and VP (P = .316) and 5y DFS rates were 22. 6% and 23.2% (P = .928), respectively.

Conclusion: Adjuvant therapy with gefitinib in patients with early-stage NSCLC and EGFR mutation demonstrated improved DFS over standard of care chemotherapy. Although this DFS advantage did not translate to a significant OS difference, OS with adjuvant gefitinib was one of the longest observed in this patient group compared with historic data.

Figures

FIG 1.
FIG 1.
Consort diagram showing patient disposition for the ADJUVANT-CTONG1104 study (data cutoff: April 19, 2020). DFS, disease-free survival; EGFR, epidermal growth factor receptor; ITT, intention-to-treat; PP, per protocol; VP, vinorelbine plus cisplatin.
FIG 2.
FIG 2.
Overall survival in the (A) ITT population and (B) PP population, and (C) subgroup analysis between gefitinib and VP groups. EGFR, epidermal growth factor receptor; HR, hazard ratio; ITT, intention-to-treat; PP, per protocol; VP, vinorelbine plus cisplatin. *Univariate test; †multivariate test.
FIG 3.
FIG 3.
Subsequent treatment in the (A) ITT population, (B) overall survival, and (C) objective response rate for subsequent treatments. CR, complete response; DFS, disease-free survival; EGFR, epidermal growth factor receptor; NC, not calculable; NR, not reached; ITT, intention-to-treat; PD, progressive disease; PR, partial response; SD, stable disease; TKI, tyrosine kinase inhibitor; VP, vinorelbine plus cisplatin. *Univariate test.
FIG 4.
FIG 4.
Updated disease-free survival for the (A) ITT and (B) PP populations. HR, hazard ratio; ITT, intention-to-treat; PP, per protocol; VP, vinorelbine plus cisplatin. *Univariate test.

References

    1. Burdett S Pignon JP Tierney J, et al. : Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev CD011430, 2015
    1. Cheng H Li XJ Wang XJ, et al. : A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer. Lung Cancer 137:7-13, 2019
    1. Yuan Y Huang Q Gu C, et al. : Disease-free survival improved by use of adjuvant EGFR tyrosine kinase inhibitors in resectable non-small cell lung cancer: an updated meta-analysis. J Thorac Dis 9:5314-5321, 2017
    1. Pisters KM Evans WK Azzoli CG, et al. : Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 25:5506-5518, 2007
    1. Xiu-Yi Zhi Jin-Ming Yu, and Yuan-Kai Shi. Chinese guidelines on the diagnosis and treatment of primary lung cancer (2015 version). Cancer 121:3165-3181, 2015. Cancer 122:162, 2016
    1. Eberhardt WE De Ruysscher D Weder W, et al. : 2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer. Ann Oncol 26:1573-1588, 2015
    1. Ettinger DS Wood DE Aggarwal C, et al. : NCCN guidelines insights: Non-small cell lung cancer, version 1.2020. J Natl Compr Canc Netw 17:1464-1472, 2019
    1. Kris MG Gaspar LE Chaft JE, et al. : Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non-small-cell lung cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. J Clin Oncol 35:2960-2974, 2017
    1. Goldstraw P Chansky K Crowley J, et al. : The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11:39-51, 2016
    1. Colt HG Murgu SD Korst RJ, et al. : Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143:e437S-e454S, 2013
    1. Deng XF Jiang L Liu QX, et al. : Lymph node micrometastases are associated with disease recurrence and poor survival for early-stage non-small cell lung cancer patients: a meta-analysis. J Cardiothorac Surg 11:28, 2016
    1. Mok TS Wu YL Thongprasert S, et al. : Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
    1. Zhong WZ Wang Q Mao WM, et al. : Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): A randomised, open-label, phase 3 study. Lancet Oncol 19:139-148, 2018
    1. Yue D Xu S Wang Q, et al. : Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): A randomised, open-label, phase 2 trial. Lancet Res Med 6:863-873, 2018
    1. Pennell NA Neal JW Chaft JE, et al. : SELECT: A phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small-cell lung cancer. J Clin Oncol 37:97-104, 2019
    1. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
    1. Gyawali B, Hey SP, Kesselheim AS: Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs. EClinicalMedicine 21:100332, 2020
    1. Mauguen A Pignon JP Burdett S, et al. : Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: A re-analysis of meta-analyses of individual patients' data. Lancet Oncol 14:619-626, 2013
    1. Oxnard GR Janjigian YY Arcila ME, et al. : Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib. Clin Cancer Res 17:6322-6328, 2011
    1. Zhou Q Song Y Zhang X, et al. : A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506). BMC Cancer 17:462, 2017
    1. Kelly K Altorki NK Eberhardt WE, et al. : Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): A randomized, double-blind, phase III trial. J Clin Oncol 33:4007-4014, 2015
    1. Zhong WZ Chen KN Chen C, et al. : Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non–small-cell lung cancer (EMERGING-CTONG 1103): A randomized phase II study. J Clin Oncol 37:2235-2245, 2019
    1. Wu YL Herbst RS Mann H, et al. : ADAURA: Phase III, double-blind, randomized study of osimertinib versus placebo in egfr mutation-positive early-stage NSCLC after complete surgical resection. Clin Lung Cancer 19:e533-e536, 2018
    1. Xu ST Xi J-J Zhong WZ, et al. : The unique spatial-temporal treatment failure patterns of adjuvant gefitinib therapy: A post hoc analysis of the ADJUVANT trial (CTONG 1104). J Thorac Oncol 14:503-512, 2019
    1. Wu YL Tsuboi M He J, et al. : Osimertinib in resected EGFR-mutated non–small-cell lung cancer. N Engl J Med 383:1711-1723, 2020

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit